Efficacy and Safety of Tirzepatide (Spartina) in Chronic Kidney Failure

What Was Tested

This registered not phased trial tested Tirzepatide.

Diabetes management presents a complex clinical scenario marked by several challenges, especially in chronic kidney failure.

These include navigating potential drug interactions between oral antidiabetic therapies and other agents.

Furthermore, these patients may experience various adverse drug effects, such as lactic acidosis, electrolyte abnormalities such as hypomagnesemia, fluid retention, and lipid derangements, which can further augment overall morbidity.

It had 1 arm (groups): Spartina (experimental).

Weekly injection of Tirzepatide (Spartina).

The registry classes the interventions as drug.

More on the Plan

Investigators will conduct a single-center clinical trial at Labafinezhad Hospital in Tehran, Iran.

Inclusion criteria consisted of age ≥18 years and a history of chronic kidney failure with preexisting diabetes or obesity with a body mass index over 27. .

Major exclusion criteria included similar drug therapy for a duration of less than 3 months and nonadherence to tirzepatide therapy.

Who Took Part

15 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

How the Study Was Run

It was run as a single-group and open-label study.

Nothing was hidden in this open-label Tirzepatide study: the participants and staff both knew the treatment.

Everyone received the same intervention, so there was no separate comparison group inside the trial.

It started in 2026-02-01 with completion listed for 2026-04-01.

It ran at 1 site in Iran.

Its stated primary purpose is treatment.

What Was Measured

Primary outcome: weight loss (time frame: kilogram of weight loss measured by same scale one and three month after injection).

What This Means in Plain Language

Put simply, this is a not phased trial of Tirzepatide in 15 people.

Its size is small, so on its own it can only give an early look.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the Tirzepatide compound page, all human trials.